A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) under normal routine practice (REAL 7)
Primary Objective
To investigate long-term safety of Sogroya (somapacitan) therapy in patients with AGHD in the setting of routine clinical practice with special focus on neoplasms and diabetes mellitus type 2.
Description
We are doing this study to collect information about how safe and effective Sogroya (somapacitan) is, when used for treatment of people with Adult Growth Hormone Deficiency (AGHD). This study has a special focus on neoplasms and diabetes mellitus type 2. Sogroya (somapacitan), which is prescribed by physicians, is commercially available in the U.S., as well as in many other countries and has been approved by regulatory authorities.
Details
Locations
University of Colorado Hospital
Principal Investigator
Christie Turin more
Study ID
Protocol Number: 23-1727
More information available at ClinicalTrials.gov: NCT05718570
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers